Skip to content

Clinical-Stage Biotechs

Can This Biotech Stock Continue Its Ascension?

The clinical-stage biotech featured in today’s article, focused on developing treatments for fibrosis, cancer and other related diseases, has gained 18.7% over the past month. In order to determine whether it can continue its ascension and become a winner in the biotech industry, the author takes a look at the factors that could influence its performance in the coming months.… 

CLICK HERE »Can This Biotech Stock Continue Its Ascension?

Higher Highs Ahead For This Hot Biotech?

The clinical-stage biotech highlighted in today’s article, dedicated to the development of first-in-class cellular immunotherapies for cancer and immune disorders, has been one of the hottest biotech stocks this year. And after a run-up that has generated triple-digit returns, there are a number of factors that could help propel it to even higher highs from here. For more on this… 

CLICK HERE »Higher Highs Ahead For This Hot Biotech?